anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
OBJECTIVE: Breast cancer treatment has evolved to the modern skin-sparing mastectomy and nipple-sparing mastectomy. To better perform these surgeries, minimally invasive techniques using the endoscope, or Da Vinci Robotic Surgery platform have been developed. The deep inferior epigastric perforator (DIEP) flap is the gold standard in breast reconstruction, but it is still not commonly performed after minimally invasive mastectomy due technical difficulty. Here the authors introduced six key steps to a successful aesthetic autologous free flap reconstruction in in minimally invasive mastectomies.
METHODS: There are six main steps to our technique: placement of mastectomy incision, precise flap design after angiography studies, trial of shaping, transcutaneous medial suture, footprint recreation and postoperative shaping with bra. Between November 2018 and July 2022, a total of 67 immediate breast reconstructions using free perforator flaps were performed in 63 patients after minimally invasive nipple-sparing mastectomy.
RESULTS: The results from the minimally invasive mastectomy group were compared with a group of conventional mastectomy patients ( n= 41) performed during the same period. There were no significant differences in flap exploration rates. One hundred percent of the flaps survived. In the minimally invasive group, the final scar was placed in the lateral region, where it would be hidden from the anterior view. Only 70.7% of the conventional mastectomy group could achieve a hidden lateral scar ( P <0.001). The aesthetic revision rates were similar between two groups.
CONCLUSION: With attention to the six steps above, autologous free flap reconstruction can be offered reliably in the setting of minimally invasive mastectomy.
INTRODUCTION: Earth's temperature has risen by an average of 0.11°F per decade since 1850 and experts predict continued global warming. Studies have shown that exposure to extreme temperatures is associated with adverse health outcomes. Missed primary care visits can lead to incomplete preventive health screenings and unmanaged chronic diseases. This study examines the associations between extreme temperature conditions and primary care utilization among adult Philadelphians.
METHODS: A total of 1,048,575 appointments from 91,580 patients age ≥ 18 years enrolled in the study at thirteen university-based outpatient clinics in Philadelphia from January 1, 2009 to December 31, 2019. Statistical analysis was performed from June to December 2023. Data on attended and missed appointments was linked with measures of daily maximum temperature and precipitation, stratified by warm and cold seasons. Sociodemographic variables and associations with chronic disease status were explored.
RESULTS: Rates of missed appointments increased by 0.72% for every 1°F decrease in daily maximum temperatures below 39°F and increased by 0.64% for every 1°F increase above 89°F. Individuals ≥ 65 years and those with chronic conditions had stronger associations with an increased rate of missed appointments.
CONCLUSIONS: Temperature extremes were associated with higher rates of missed primary care appointments. Individuals with chronic diseases were more likely to have missed appointments associated with extreme temperatures. The findings suggest the need for primary care physicians to explore different modes of care delivery to support vulnerable populations, such as making telemedicine during extreme weather events a viable and affordable option.
In the side lying position, lumbar chiropractic manipulation will be performed over the transverse process of the vertebra thought to have vertebral subluxation. A total of 8 sessions of chiropractic manipulation will be performed 2 times a week.
1. A compound having the formula or a N-oxide form, a pharmaceutically acceptable addition salt or a stereochemically isomeric form thereof, wherein: Alk is 1,5-pentadiyl; n is 1 or 2; p is 1 and q is 2; or p is 2 and q is 1; X is -O-, -S-, or NH; each R<1> is independently hydrogen, halogen, C1-6alkyl, nitro, hydroxy or C1-4alkyloxy; R<2> is hydrogen, C1-6alkyl, aryl or C1-6alkyl substituted with aryl; aryl is phenyl or phenyl substituted with a halogen or C1-6alkyl; D is a radical of formula wherein m is 1 or 2; each R<3> independently is hydrogen, C1-4alkyl, C1-4alkyloxy or halo. 2. A compound according to claim 1 wherein n is 1 and R<1> is hydrogen, chloro, fluoro, methyl, methoxy or nitro. 3. The use of a compound according to any one of claims 1 or 2 as a medicine. 4. The use of a compound as claimed in any one of claims 1 or 2 in the manufacture of a medicament for treating depression or Parkinson's disease. 5. A composition comprising a pharmaceutically acceptable carrier and, as active ingredient, a therapeutically effective amount of a compound as claimed in any one of claims 1 and 2. 6. A process for preparing a composition according to claim 5 by combining a compound as defined in any one of claims 1 and 2 as the active ingredient in intimate admixture with a pharmaceutically acceptable carrier. 7. A process for preparing a compound of formula (I) according to claim 1, comprising: a) N-alkylating an intermediate of formula (II) with an alkylating reagent of formula (III) wherein W<1> is a suitable leaving group and D, Alk, X, n and R<1> are as defined in claim 1, in a reaction-inert solvent, in the presence of a base and optionally in the presence of a catalyst; b) and if desired, converting compounds of formula (I) into each other following art-known transformations, and further, if desired, converting the compounds of formula (I), into a therapeutically active non-toxic acid addition salt by treatment with an acid, or into a therapeutically active non-toxic base addition salt by treatment with a base, or conversely, converting the acid addition salt form into the free base by treatment with alkali, or converting the base addition salt into the free acid by treatment with acid; and, if desired, preparing stereochemically isomeric forms or N-oxides thereof.
1,131,285. Ethers of propargyl alcohol. DELALANDE S.A. 19 Oct., 1966 [27 July, 1965], No. 31936/65. Heading C2C. Novel compounds of Formula I, in which R 1  is hydrogen or methyl, R 2  is hydrogen, hydroxy, carbamoyloxy or C 1-5  alkyl, R 3  is hydrogen, saturated or unsaturated C 1-7  hydrocarbyl, phenoxyethyl, haloalkyl, carbamoyloxy, α- or #-naphthyl, aminoalkyl of formula -(CH 2 ) m R 4 , where m is 1 to 4 and R 4  is a tertiary aliphatic or heterocyclic amino group, cyanoalkyl of formula -(CH 2 ) p -CN, where p is 2, 3 or 4, aralkyl or aralkenyl of Formula II where X is C 1-3 alkylene or C 2-3  alkenylene, aryl of Formula III where one of R 5  and R 6  is hydrogen and the other is methoxy, chlorine, saturated or unsaturated aliphatic C 1-5 hydrocarbyl, trifluoromethyl, acetyl or propionyl, or both of R 5  and R 6  are each hydrogen, chlorine, bromine, alkyl or methoxy, are prepared by halogenating a compound of Formula IV and then dehydrohalogenating the resulting dihalo compound, or (for compounds in which R 1  is H and R 2  is OH) by either reacting 1-propargyl- 2,3-epoxypropane with a compound of formula R 3 -OM, where R 3  is as defined above except for hydrogen and M is hydrogen or an alkali metal, or by reacting a compound of Formu la V in which R 3  is as defined above except for hydrogen, with propargyl alcohol. 1-Propargyloxy-2,3-propanediol is also prepared by alkylating 2,3-isopropylidene-glycerol with a propargyl halide to form 2,2-dimethyl-4-propargyloxymethyl-dioxolane followed by splitting the dioxolane ring by dilute hydrochloric acid, or by hydrolysing 1 -propargyloxy-2,3- epoxypropane. The 3-monocarbamate and 2,3-dicarbamate esters are also prepared by reacting the corresponding alcohols with phosgene and reacting the resulting chlorocarbonates with ammonia. 1-Allyloxy-3-butoxypropane is prepared by treating 1,3-propanediol in boiling toluene, in the presence of sodium, successively with butyl bromide and allyl bromide.
Serious, life-threatening, and fatal infusion-related reactions characterized by one or more of the following symptoms can occur with doxorubicin hydrochloride liposome injection: flushing, shortness of breath, facial swelling, headache, chills, chest pain, back pain, tightness in the chest and throat, fever, tachycardia, pruritus, rash, cyanosis, syncope, bronchospasm, asthma, apnea, and hypotension. Of 239 patients with ovarian cancer treated with doxorubicin hydrochloride liposome injection in Trial 4, 7% of patients experienced acute infusion-related reactions resulting in dose interruption. All occurred during cycle 1 and none during subsequent cycles. Across multiple studies of doxorubicin hydrochloride liposome injection monotherapy including this and other studies enrolling 760 patients with various solid tumors, 11% of patients had infusion-related reactions. The majority of infusion-related events occurred during the first infusion.

Ensure that medications to treat infusion-related reactions and cardiopulmonary resuscitative equipment are available for immediate use prior to initiation of doxorubicin hydrochloride liposome injection. Initiate doxorubicin hydrochloride liposome injection infusions at a rate of 1 mg/min and increase rate as tolerated [see Dosage and Administration (2.6)]. Withhold doxorubicin hydrochloride liposome injection for Grade 1, 2, or 3 infusion-related reactions and resume at a reduced infusion rate. Discontinue doxorubicin hydrochloride liposome injection infusion for serious or life-threatening infusion-related reactions.
In this trial, participants will be randomly assigned to receive either fluoxetine or placebo. Treatment will consists of two phases (acute treatment and maintenance). In the acute treatment phase, participants will receive fluoxetine or placebo daily for 12 weeks. Participants will be followed every 2 weeks. In the Maintenance phase, participants showing significant improvement after 12 weeks may continue treatment for an additional 6 months. In this phase, participants are followed every 4 weeks.

Participants who do not improve during the acute treatment phase may receive open fluoxetine, or another appropriate medication, for 3 months.
Additional subjects will be recruited to further explore the safety, tolerability, PK, and efficacy in specific subject subgroups. One or more RP2D may be explored. Definition of these cohorts will be accomplished by protocol amendment, and in light of emerging data from Phase 1a.
FIELD: biotechnology. SUBSTANCE: the cell strain doesn't express tumor markers but it expresses metabolic markers that are specific for human non- immortalized epithelium cells and markers for metabolic differentiation that are specific for nonimmortalized human large intestine epithelial cells. This cell strain is able to attach the strain CNCM-1225 of lactic acid microorganism in vitro. Serum-free cultural medium comprises trace elements, vitamins (vitamin C and retinoic acid), hormones (triiodothyronine, dexamethasone, hydrocortisone, bovine hypophysis extract, insulin, epidermal growth factor) and transferrin. Immortalization of human large intestine epithelial cells is carried out by preparing culture of primary epithelial cells isolated from human large intestine followed by infection with recombinant virus. Invention provides the identification of mutagenic, toxic or favorable effect of agent on metabolism of intestine tract cells. Invention can be used for preparing strain of immortalized cells of human large intestine epithelium. EFFECT: improved methods, valuable properties of cells. 16 cl, 3 dwg, 4 tbl, 2 ex
INTRODUCTION: The relationship between BMI and early renal function recovery after kidney transplantation is important due to the rising global obesity rates.
METHODS: A retrospective study on 320 patients who received allograft kidney transplantation at Guangxi Medical University Hospital explored the BMI-kidney function relationship using various statistical methods. Mendelian randomization (MR) was also employed to investigate causality.
RESULTS: Based on the univariate analysis, multivariate linear regression models, and trend analysis, it was found that there were significant positive correlations between BMI and creatinine, urea, and cystatin C on the 7th day after kidney transplantation (p < 0.05). The sensitivity analysis further confirmed these correlations in different gender stratification, adolescents, and adults. However, the positive correlation with cystatin C was only significant in males. Additionally, after conducting smooth curve fitting analysis and threshold saturation analysis, it was revealed that the negative correlation between early renal function recovery was most significant when BMI was between 22.0 and 25.5 kg/m2, and early postoperative renal function may be optimal when BMI was at 22.2 kg/m2. Finally, the MR analysis confirmed a causal relationship between BMI and renal failure, as indicated by the IVW method (p = 0.003), as well as the weighted median estimator (p = 0.004).
CONCLUSION: This study on kidney transplant patients found that maintaining a BMI within the range of 22.0-25.5 kg/m2, with an optimal BMI of 22.2 kg/m2, improves early renal function recovery. This correlation holds true for different age-groups and genders. Monitoring and controlling BMI in high-risk patients can enhance post-transplantation renal function.
Patients will be randomly allocated to one of two groups. In the Chinese Tuina group (group CTG), patients will receive the traditional Chinese Tuina therapy (including rolling, grasping, scratching, pressing, acupressure or pushing) on the basis of KOA health education and home-exercise. Patients in the Physical Manual group (group PMG) will receive the modern physical manual therapy (including joint mobilization/manipulation, manual traction, soft tissue manipulations, passive stretching, range of motion and strength training) on the basis of KOA health education and home-exercise. Assessments will be conducted at baseline and 4 and 16 weeks after randomization.

It is expected that the interventions will alleviate the sufferings of the patient. The risks of participation are minimal. Occasionally, tuina can make people feel nauseous or experience a temporary increase in pain either during or after treatment. Rare side effects happen during and after Tuina or manual treatment.
PROBLEM TO BE SOLVED: To prepare a hair growth composition having high safety when used for a long period and having sufficient hair growth effects by using an extract prepared by extracting a specific plant as an active ingredient. SOLUTION: This hair growth composition is prepared by using an extract obtained by extracting a plant belonging to the genus Stevia Cav. such as the one (the whole herb, a leaf, a stem, a root, a flower, a fruit, etc.), e.g. Stevia rebaudiana Bertoni or Stevia rebaudiana Hemsl with an organic solvent such as ethanol. The extracted ingredient having hair growth actions may be produced by the chemical synthesis or may be obtained by the extraction from a relative plant of the genus Stevia Cav. having the same hair growth ingredient as that of the stevia extract having the hair growth actions.
BACKGROUND: Alzheimer's disease (AD) is one of the most common neurodegenerative diseases leading to dementia in elderly people. Microglia-mediated neuroinflammation plays an important role in AD pathogenesis, so modulation of neuroinflammation has emerged as an essential therapeutic method to improve AD. The current study aims to investigate whether MKP-1 can regulate microglia phenotype and inflammatory factor release in AD and explore its possible mechanisms.
METHODS: Amyloid precursor protein/PS1 double transgenic mice and wild-type mice were selected to study the locations of microglia and amyloid-β (Aβ) plaques in different regions of mice brains. Changes in MKP-1 of microglia were detected using AD model mice and AD model cells. Changes in phenotype and the release of inflammatory factors within immortalized BV2 murine microglia were investigated by regulating the expression of MKP-1.
RESULTS: The distribution of microglia and Aβ plaques in the AD brain was region-specific. MKP-1 expression was downregulated in AD mice, and in vitro, with increasing Aβ concentrations, MKP-1 expression was reduced. MKP-1 over-expression increased M2 microglia but decreased M1 microglia accompanied by changes in inflammatory factors and inhibition of MKP-1 yielded the opposite result.
CONCLUSION: MKP-1 regulated microglia phenotype and inflammatory factor release in AD through modulation of the p38 signaling pathway.
Methods and systems to enable users to select and compile personal care information filtered by the selection of a specific care concern or diagnosis, filtered by the user's geographic location, and filtered by available health care benefits. The method and system may provide information concerning home care assistance, transportation options, respite care, child care, home maintenance, shopping, pet care, technology, meal preparation, case management and advocacy services. Users may store information and post saved information to multiple planning boards for future reference or to share with others. The system and method may provide the total costs of services listed within the filtered information. Information concerning volunteer or barter opportunities may be provided to the user. The health care information may include links to various community, non-profit and governmental assistance entities. Users may purchase or be awarded credits to assist themselves or fellow users to access and utilize services contained within the system.
A solid hair cosmetic composition comprising 0.1-40 % of at least one polysaccharide, where at least one polysaccharide is corn, rice, potato, or tapioca starch, modified starch, and/or a dextrin (preferably maltodextrin). The composition optionally comprises: 10-60 % polyhydric alcohol, preferably glycerol; 0.1-15 % cationic surfactant, preferably alkylquats, quaternary imidazolines, or C8-C30-alkyl-tri-C1-C4-alkylammonium salts; and 0.1-15 % of at least one saturated or unsaturated, branched or unbranched C8-C30 alcohol and/or carboxylic acid or salt thereof. The fatty alcohol is preferably cetyl or stearyl alcohol, and the fatty acid is preferably coco, lauric, myristic, palmitic, stearic, behenic, oleic acids or their salt. The composition may be in the form of a pen or piece. The composition is produced by mixing all the ingredients with sufficient heat/agitation to melt and evenly distribute, before cooling and solidification, preferably using pin/piece moulds. The cosmetic is applied to wet hair or mixed with water and applied to hair.
PROBLEM TO BE SOLVED: To improve the flexibility, smoothness, antistatic properties, handleability of a base material, and appearance by adding a specified coupling agent (also called a hydroxylaed ester) and a homogeneous liquid product comprising a cationic reagent. SOLUTION: The coupling agent used is selected from compounds represented by formula I [wherein RA is a 1-14C alkyl, which can be substituted by 1 to 3 hydroxyl groups; RC is a 1-10C alkyl which can be substituted by 1 to 3 hydroxyl groups, or can be substituted by substituent(s) represented by the formula -OC(O)-RE; and RE is a 1-14C alkyl which can be substituted by hydroxyl group(s)]. An example of the compound preferably used is 2, 2, 4-trimethyl-1, 3-pentandiol monoisobutyrate. An example of the cationic reagent used is an alkylenediamine [e.g. one represented by formula II (wherein R1 is noncyclic alkyl, alkylene or a 12-21C hydrocarbon group; Z is -(R2 O)0-4 H; and R2 and R3 are each a divalent 1-6C alkylene]. The coupling agent is blended with the cationic component preferably at a weight ratio of (1:10) to (1:1).
Restoration of blood flow in skeletal muscle after a prolonged period of ischemia induces muscular ischemia-reperfusion injury, leading to local injury/dysfunction in muscles followed by systemic inflammatory responses. However, preventive/curative agents for skeletal muscle ischemia injury are unavailable in clinics to date. Increasing evidence has validated that carbon monoxide (CO) prevents the progression of ischemia-reperfusion injury in various organs owing to its versatile bioactivity. Previously, we developed a bioinspired CO donor, CO-bound red blood cells (CO-RBC), which mimics the dynamics of RBC-associated CO in the body. In the present study, we have tested the therapeutic potential of CO-RBC in muscular injury/dysfunction and secondary systemic inflammation induced by skeletal muscle ischemia-reperfusion. The results indicate that CO-RBC rather than RBC alone suppressed elevation of plasma creatine phosphokinase, a marker of muscular injury, in rats subjected to both hind limbs ischemia-reperfusion. In addition, the results of the treadmill walking test revealed a significantly decreased muscular motor function in RBC-treated rats subjected to both hind limbs ischemia-reperfusion than that in healthy rats, however, CO-RBC treatment facilitated sustained muscular motor functions after hind limbs ischemia-reperfusion. Furthermore, CO-RBC rather than RBC suppressed the production of tumour necrosis factor (TNF)-α and interleukin (IL)-6, which were upregulated by muscular ischemia-reperfusion. Interestingly, CO-RBC treatment induced higher levels of IL-10 compared to saline or RBC treatments. Based on these findings, we suggest that CO-RBC exhibits a suppressive effect against skeletal muscle injury/dysfunction and systemic inflammatory responses after skeletal muscle ischemia-reperfusion.
This study capitalizes on a contract with the Oregon Department of Human Services Child Welfare to implement KEEP state wide in Oregon with a focus on increasing access to services for minority youth populations. To help the child welfare system meet their goal of achieving health equity, adaptations to the KEEP curriculum have been made for minority groups, and KEEP is being delivered in "affinity groups". Affinity KEEP groups are tailored to meet a specific population's needs and are comprised of parents who all share a common interest, purpose, or key characteristic. To date, Affinity KEEP groups are being offered for foster/kin parents of populations defined by sexual and gender minority youth and Native youth, and for Spanish-speaking parents. The curriculum is currently being revised for transracial foster/kin placements where the youth and one or more parents are of a different race/ethnicity. The current proposal seeks to study N = 166 new families, as part of the ongoing Oregon KEEP implementation, and aggregate existing data from four KEEP studies to use propensity score matching to reduce selection bias and strengthen causal inferences that can be drawn from the potential benefits of providing KEEP to underserved minority populations. By leveraging two decades worth of data on the KEEP intervention and using state-of-the-art data harmonization techniques and a quasi-experimental design, this study affords a rigorous evaluation of whether tailoring the KEEP curriculum to minority populations' specific needs, and providing KEEP to foster/kin parents, improves youth mental health outcomes (i.e., depression/anxiety, post-traumatic stress disorder symptoms, suicidality, and externalizing behaviors) (Aim 1). The study could have a wide reach, impacting our understanding of how to improve and inform equitable delivery of services to youth and families involved in the child welfare system, and effectively address youth mental health disorders and improve care quality and long-term outcomes for a high-risk, underserved population of youth.
Randomized Arm 2 will get anticoagulation therapy with low molecular weight heparin (LMWH) with or without a transition to warfarin. There are three FDA-approved LMWH drugs that may be used for this study: Dalteparin, Enoxaparin, or Fondaparinux. The treatment (including dosage form, dosage, frequency and duration) should be administered in accordance with the drug's FDA package insert, and all modifications are at the discretion of the treating investigator.